ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
Jefferies London Healthcare Conference November 14, 2018at 9:40 am ET/ 2:40 pm GMT
- Evercore ISI HealthConX
November 27, 2018at 8:45 am ET
- 30th Annual
Piper Jaffray Healthcare Conference November 28, 2018at 11:30 am ET
A webcast of each presentation will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
INVESTOR RELATIONS CONTACT
Sarah Kiely, 781-895-0600
THRUST Strategic Communications
Chelcie Lister, 910-777-3049
Courtney O’Konek, 781-895-0600
Robert Stanislaro, 212-850-5657